Baseline OCT cyst morphology and 24-month treatment outcomes in diabetic macular oedema: the BOSPHORUS-DME Study Group
The BOSPHORUS-DME study demonstrates that while anti-VEGF therapy yields significant visual improvements across all baseline ESASO cyst stages of diabetic macular oedema over 24 months, eyes with advanced (Stage 3) cyst morphology exhibit a unique late-phase visual decline and require more intensive treatment, suggesting this staging system serves as a valuable prognostic marker for monitoring.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Diabetes can damage the tiny blood vessels throughout the body, but one of its most devastating effects occurs in the eye. When high blood sugar causes fluid to leak into the retina, the light-sensitive layer at the back of the eye, it creates a condition called diabetic macular edema. This swelling blurs central vision, which is essential for reading, driving, and recognizing faces. In many cases, this fluid gathers in small, bubble-like pockets within the retinal tissue, forming what doctors call cysts. For decades, the standard treatment has been injections of medicine directly into the eye to stop the leakage and dry out the swelling. While these treatments often work well in the short term, doctors have long wondered why some patients maintain their vision gains for years while others see their vision slowly slip away again, even when they continue to receive care.
A large team of eye specialists in Turkey recently set out to solve this puzzle by looking closely at the shape and size of those fluid pockets before treatment even began. They studied hundreds of patients over two years, tracking how their vision changed in relation to the specific pattern of cysts visible in their eye scans. The researchers found that while the most severe cases of swelling responded dramatically at first, they also carried a hidden risk: a small but measurable decline in vision that appeared late in the treatment process, a pattern that did not happen in milder cases.
The study, conducted across ten medical centers in Istanbul, focused on 311 eyes from patients who had never received injections for their eye swelling before. The team used a specific grading system to sort the patients into three groups based on the appearance of their fluid pockets. The first group had small, mild cysts that did not touch the very center of vision. The second group had moderate cysts that were beginning to affect the center. The third and largest group had advanced, severe cysts that were large, merged together, and had already disrupted the delicate outer layers of the retina. The researchers then followed these patients for twenty-four months, recording their vision and the thickness of their retinas at regular intervals while they received standard care, which involved a series of initial injections followed by additional treatments as needed.
The results showed a clear story of two different phases. In the first year, the patients with the most severe cysts showed the most dramatic improvement. Because they started with the worst vision, they had the most room to gain, and nearly half of them improved by three lines on an eye chart within the first twelve months. This was a significant victory, proving that even the most damaged eyes can recover substantial vision with treatment. However, the story changed as time went on. Between the eighteen-month and twenty-four-month marks, the group with the most severe cysts began to lose a small amount of the vision they had fought so hard to regain. Their vision dropped by a tiny but statistically significant amount, roughly equivalent to one line on an eye chart. In contrast, the patients with mild and moderate cysts held steady; their vision did not slip during this same period.
Crucially, the researchers investigated whether this late decline was caused by the doctors not treating the severe cases enough. They checked if the patients with severe cysts received fewer injections, different medicines, or fewer steroid implants than the others. They found the opposite to be true. The patients with the most severe cysts actually received more treatments, more frequent visits, and were more than twice as likely to need additional steroid implants to manage their condition. Despite this extra effort and more intensive care, their vision still declined slightly in the final six months. This suggests that the decline was not a failure of the treatment plan, but rather a characteristic of the disease itself in its most advanced form. The severe cysts may cause a type of lasting damage to the light-sensitive cells that cannot be fully reversed, even when the swelling is successfully reduced.
The study also looked at the physical thickness of the retina. While the severe cases saw their swelling go down significantly, the fluid began to creep back slightly in the final months, mirroring the small drop in vision. This indicates that the eye was struggling to maintain a dry state over the long term. The researchers concluded that the initial appearance of the cysts serves as a useful warning sign. If a patient starts with the most advanced stage of cysts, they are likely to see great improvement at first, but they may also be at higher risk for a slow, late-stage decline that requires closer monitoring. This finding does not mean the treatment fails, but it does suggest that doctors should watch these specific patients more carefully as time goes on, perhaps adjusting their care earlier to prevent that final, subtle loss of sight. The work highlights that while modern medicine can restore vision in even the most difficult cases, the journey is not always a straight line, and the starting point of the disease influences the long-term path.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.